(Stroke. 1997;28:1574-1578.)
© 1997 American Heart Association, Inc.
Articles |
From the Service de Cardiologie (A.C., C.C.) and Neurologie (C.T., I.C., M-G.B., P.A.), Hôpital Saint-Antoine, Université Pierre et Marie Curie, Paris; INSERM U 360 Recherches épidémiologiques en Neurologie et Psychopathologie, Hôpital de la Pitié-Salpétrière (C.T.), Paris; and the Cliniques Cardiologiques des Centres Hospitaliers Universitaires de Grenoble (B.B.), Besançon (Y.B.), Lille (L.G.), and Dijon (S.F.), France.
Correspondence to Ariel Cohen, MD, PhD, Service de Cardiologie, Hôpital Saint-Antoine, Université Pierre et Marie Curie, 184, rue du faubourg St-Antoine, 75571 Paris, Cedex 12, France. E-mail ariel.cohen{at}sat.ap-hp-paris.fr
| Abstract |
|---|
|
|
|---|
Methods Using transesophageal echocardiography, we compared the frequency of strands on native mitral valves in 284 consecutive patients admitted with brain infarction and 276 control patients, all older than 60 years. In a second part, case subjects were followed up over a 2- to 4-year period, and the risk of recurrence of brain infarction was estimated in patients with and without strands.
Results In the case-control study, mitral valve strands were found in 22.5% of the case patients and in 12.1% of the control subjects. In case subjects, mitral valve strands were more frequent in those with mitral valve dystrophy (52.4% versus 37.4%; P=.03). Strands were not associated with mitral valve prolapse, annular calcifications, or left atrial spontaneous echocardiographic contrast. After adjustment for age, sex, and mitral valve dystrophy, the odds ratio for ischemic stroke among patients with mitral strands was 2.2 (95% confidence interval, 1.4 to 3.6; P=.005). The frequency of strands was not different in patients with a known cause of brain infarction (24.4%) from that in patients with no other apparent cause (20.9%). During 646 per 100 person-years of follow-up, the incidence of recurrent brain infarction was 6.0 person-years in patients with strands and 4.2 in those without. In the Cox analysis, including potential confounders and poststroke treatment, mitral valve strands did not appear as independent predictors of recurrent brain infarction (relative risk, 1.3; 95% confidence interval, 0.5 to 3.0; P=.54).
Conclusions The present study shows an independent association between mitral valve strands and the risk of brain infarction. However, the lack of an increased relative risk of recurrence raises doubts about the potential causal relation with brain infarction in patients aged 60 years or older.
Key Words: cardioembolic stroke cerebral infarction mitral valve transesophageal echocardiography
| Introduction |
|---|
|
|
|---|
The aims of the present study were to determine the risk factors associated with mitral valve strands and the frequency of strands in consecutively admitted patients with brain infarction compared with control subjects. In addition, we sought to evaluate the relative risk of recurrent brain infarction in case subjects with and without strands.
| Subjects and Methods |
|---|
|
|
|---|
Case-Control Study
Three hundred thirty-eight patients older than 60 years admitted
to neurology departments for brain infarction were included between
September 1991 and October 1993. The following risk factors were
recorded: hypertension,
hypercholesterolemia, cigarette smoking,
diabetes mellitus, past myocardial infarction, peripheral
artery disease, and atrial fibrillation. Patients underwent a
diagnostic workup, including cranial CT imaging or MRI of
the brain, ultrasound examination of cervical arteries, 12-lead
electrocardiography, and
transesophageal echocardiography.
Patients were then divided according to the presumed cause of the
stroke: likely cause, lacunar infarct, another possible cause, and no
apparent cause.13 Three patients with valvular
prostheses were excluded, leaving a total of 335 patients in the final
sample.
The control group consisted of 276 patients with no history of brain embolization or peripheral embolization who underwent transesophageal echocardiography for cardiac conditions such as mitral or aortic valvulopathy, ischemic or idiopathic left ventricular systolic dysfunction, atrial fibrillation, and miscellaneous causes. The latter included endocarditis, intracavitary masses, suspicion of aortic dissection, pulmonary embolism, and inadequate transthoracic echocardiogram. Risk factors were recorded at the time of examination.
Transesophageal Echocardiography
Transesophageal
echocardiography was performed by trained
cardiologists who had no information on the etiology of brain
infarction. The examinations were recorded on videotapes for
further off-line analysis. Transesophageal
echocardiography was performed within 2 weeks after
the onset of stroke, according to standard techniques.9 We
used commercially available imaging systems (VingMed CFM 700, CFM 800,
Hewlett-Packard Sonos 1000, and Acuson 128XP) with a 5-MHz single-plane
probe in 428 patients, a biplane probe in 110 patients, or a multiplane
probe in the last 73 patients.
A complete examination of cardiac structures for cardiac and aortic
sources of embolism was performed. Left atrial and appendage thrombus,
spontaneous echocardiographic contrast, atrial septal
aneurysm, patent foramen ovale, mitral valve prolapse, and
atherosclerotic plaques in the ascending aorta and arch were defined
according to previously described criteria.13 14 Mitral
valve strands were recognized as thin and filamentous attachments on
the atrial surface of mitral leaflets,
1 mm in width, 1 to
20 mm in length, moving independently from the valves, in and out
of the imaging plane (Fig 1
). They were
differentiated from ruptured chordae tendineae, which appear as a
fluctuating linear echo with high-frequency fluttering chordae in the
left atrial cavity during systole. Sessile or pedunculated
valvular lesions >1 mm in width were not described as
strands. Mitral valve dystrophy was defined as a valve thickness
3 mm by transesophageal two-dimensional
echocardiography.15 Mitral annular
calcifications were defined as the presence of a cluster of dense
high-intensity echoes between the posterior left
ventricular wall and the posterior mitral
leaflet.16
|
Follow-up Study
Case patients were followed up for 2 to 4 years to assess new
vascular events, as described elsewhere.17 The incidence
of recurrent brain infarction was compared in patients with and without
strands.
Statistical Analysis
In the case-control analysis, risk factors for strands
were studied in case patients and control subjects, including
demographic factors and cardiac morphological abnormalities. The
frequencies of strands in both groups were then compared and expressed
as a crude odds ratio. Adjusted odds ratios were estimated through
unconditional logistic regression.
To estimate the impact of the referral diagnosis in control subjects on the risk estimation, we used the data of one center that included the largest number of case and control subjects (Saint-Antoine Hospital, 57% of the sample). Control subjects were classified in four broad categories of indication for transesophageal echocardiography. The frequency of strands and odds ratios for brain infarction in patients with strands were then estimated. Homogeneity of the odds ratios was tested by the Breslow and Day test.18
In the follow-up study, we computed rates of incidence by dividing the number of new cases of brain infarcts by the number of person-years in the groups of patients with and without strands. Cox models were used to estimate the relative risk of recurrent brain infarction in patients with mitral valve strands after controlling for potentially confounding factors. Two models were created: the first one included variables such as sex, age, and treatment; the second model included the same variables and potential causes of brain infarction: carotid stenosis >70%, plaques of the aortic arch, and atrial fibrillation. All reported probability values are two-tailed. Data were analyzed with the use of SAS19 and BMDP software.20
Videotapes of the transesophageal examinations were
reviewed by one of us (A.C.), randomly and without knowledge of the
status of the subject. Because we used strict criteria to recognize the
presence of strands, we considered the information to be missing when
the examination of the mitral valve was considered suboptimal for this
specific question, mainly for technical reasons (
10 cardiac cycles in
the tape). Thus, information was lacking in 12% of the patients. In
addition, the videotaped examinations of 53 randomly selected patients
and control subjects were also reviewed by a senior
echocardiographer (C.C.), according to the same protocol.
The level of agreement between the two observers was 86.8%, and the
Cohen's
index was 0.65.
| Results |
|---|
|
|
|---|
|
Information on strands was missing in 12% of the patients (51 case subjects and 20 control subjects). In the remaining patients, mitral valve strands were found in 22.5% of the patients (64/284) and 12.1% of the control subjects (31/256), yielding a crude odds ratio of 2.1 (95% confidence interval, 1.3 to 3.4; P<.005).
Risk factors for strands were studied separately in patients and
control subjects (Table 2
). Patients with
strands were more frequently men, although not significantly, and they
more frequently had mitral valve dystrophy. The presence of strands was
independent of age. Control subjects with strands were significantly
older, but there was no significant difference in sex or frequency of
mitral valve dystrophy. There was no difference in patients with or
without strands in both groups with regard to other potential risk
factors for brain infarct.
|
A multivariate unconditional logistic regression model was used to control for potentially confounding variables: age, sex, and mitral valve dystrophy. The adjusted odds ratio was 2.2 (95% confidence interval, 1.4 to 3.6; P=.001). A model that also included hypertension, cigarette smoking, atrial fibrillation, aortic arch plaques, left atrial spontaneous echocardiographic contrast, and atrial septal aneurysm gave a comparable estimate, with an adjusted odds ratio of 2.1 (95% confidence interval, 1.3 to 3.6; P=.005).
The frequency of strands in patients according to the cause of stroke was as follows: 24.4% (22/90) in patients with a likely cause, 21.6% (11/51) in patients with a lacunar infarct, 23.1% (12/52) in patients with a possible cause, and 20.9% (19/91) in patients with no other apparent cause.
Frequency of Strands in Control Subjects According to Referral
Diagnosis
Among 149 control patients referred to the Saint-Antoine center
for transesophageal
echocardiography, the four following categories of
cardiac conditions were considered: mitral valve disease (n=61),
ischemic and idiopathic cardiomyopathy
(n=39), aortic valve disease (n=11), and miscellaneous causes (n=38).
Table 3
shows the risk estimates when
case patients of Saint-Antoine Hospital (n=175) were compared with each
control category. The corresponding crude odds ratios varied from 1.4
in the miscellaneous group to 3.7 in the
cardiomyopathy group. However, homogeneity between
the odds ratios was not rejected by the Breslow and Day test (Breslow
and Day statistic=2.45, P=.484). The global crude odds ratio
for the Saint-Antoine center was 2.2, close to that found in the
overall population.
|
Follow-up Study in Patients
Among our study population of 335 patients, 51 had missing
information on strands. Thus, 284 patients were followed for a mean of
2.3 years. During the 646 person-years of follow-up, a recurrent brain
infarction was observed in 29 cases. The incidence was 6.0 per 100
person-years in patients with strands (7 events) and 4.2 in patients
without strands (22 events). Information on postqualifying event
treatment was available in 264 case patients: 66.3% (175/264) were
treated with antiplatelet drugs, 20.8% (55/264) were treated with
oral anticoagulants, and 12.9% (34/264) received no antithrombotic
treatment. In patients with strands, the incidence rate of stroke was
7.1 per 100 person-years in patients receiving antiplatelet drugs,
6.9 in those receiving oral anticoagulants, and 0 in those with no
antithrombotic treatment.
In the multivariate Cox model adjusted for age and sex,
the relative risk of stroke in patients with strands was 1.3 (95%
confidence interval, 0.6 to 3.1). In a model including age, sex,
treatment, and likely sources for stroke (atrial fibrillation, carotid
stenosis, aortic arch plaques), the relative risk was 1.3 (95%
confidence interval, 0.5 to 3.0; P=.54). The two
Kaplan-Meier curves in patients with and without mitral valve strands
were not significantly different from one another (Fig 2
).
|
| Discussion |
|---|
|
|
|---|
First, the risk might be upwardly biased in our case-control study. Consecutiveness of patient recruitment, systematization of the transesophageal echocardiographic examination, and review of the videotapes by an echocardiographer unaware of patient status were used to avoid a systematic bias in the estimation of the frequency of strands. In fact, the knowledge of patient status may influence the rigor for the search of strands. In the only study with a design comparable to our study, Lee et al3 described mitral valve strands in 11 of 50 patients (22%) referred for ischemic stroke or transient ischemic attacks, an estimation close to that we found. In a recent report by Freedberg et al,4 the estimated risk was found to be much higher than that found in our study. However, that study included only patients referred for transesophageal echocardiography, and the referral diagnosis for control subjects was not indicated, leaving the possibility of an overestimation of the risk.
Second, overestimation of the risk might be related to an underestimation of the frequency of strands in control subjects.21 This point is critical in studies in which exposure is determined through a noninvasive procedure. Control subjects referred for transesophageal echocardiography represent a selected group of patients.22 To test this hypothesis, we studied the frequency of strands by referral diagnosis. We found that the frequency of strands varied in the four categories of indication for transesophageal echocardiography in control subjects from 7.7% of those referred for left ventricular dysfunction to 18% of those referred for aortic valve disease. Remarkably, the miscellaneous group, which is often less exposed to recruitment bias, had the highest frequency of patients with strands (18.4%). When case subjects were compared with this group, the estimated odds ratio was not significantly increased and was close to the relative risk obtained in the follow-up study. Strands were detected in 2.3% of control subjects in the study of Freedberg et al4 and in 0.3% of those evaluated in the study of Tice et al.5 Thus, in both studies the incidence of mitral valve strands in control subjects was under the lowest estimate found in our study. These results highlight the caution needed when estimating the risk associated with strands in case-control studies when control subjects are referred for transesophageal echocardiography.
In the follow-up study, the risk estimate for recurrent brain infarction was 1.3, which is not significantly different from 1.0. The risk estimate is not directly comparable to the one estimated in the case-control study because only case subjects were followed up and recurrent strokes were studied. In addition, the relatively small number of recurrent brain infarctions might restrict our ability to detect a significant increase of the risk in patients with strands. Another explanation for the lower than expected risk estimate in the follow-up study might be that since their qualifying vascular event, patients were treated with antithrombotic drugs, thus reducing the risk of recurrent brain infarction. However, our results did not confirm this hypothesis because we found that brain infarction recurrence in patients with strands was the lowest in those who received no antithrombotic therapy.
Our study contains other evidence against strands as a major source of embolism. If strands were a powerful source of brain embolism, one could expect a higher frequency of strands in patients with no other detectable cause. In fact, we found a similar prevalence of strands in patients with a likely source of brain infarction and in those without any detectable cause.
In our study as well as that of Lee et al,3 mitral valve thickening as shown by transesophageal echocardiography was associated with a higher incidence of mitral valve strands compared with valves without thickening. This fact supports the assumption that strands may represent a degenerative process of leaflet tissue. However, the exact nature of valvular strands remains undetermined. Lee et al3 suggested that mitral valve strands were consistent with Lambl's excrescences. Whether strands on native mitral valves identified by transesophageal echocardiography and Lambl's excrescences described in pathological reports10 12 23 represent the same morphological entity is currently unknown.
Conclusion
We found that strands were significantly associated with the risk
of stroke. However, our data suggest that this association might be
related in part to a referral bias in control subjects. Nevertheless,
our follow-up study indicates that, in patients with strands, no
specific treatment, medical or surgical, has to be considered.
| Acknowledgments |
|---|
| Footnotes |
|---|
A complete list of the participants in this research study appears at the end of this article.
| Appendix 1 |
|---|
|
|
|---|
Paris, Saint-Antoine Hospital, Pierre and Marie Curie University: Department of NeurologyPierre Amarenco, MD (principal investigator); Olivier Heinzlef, MD; Christian Lucas, MD; Pierre-Jean Touboul, MD (cranial ultrasound study design); Jean-Luc Gérard, MD; Valérie Adraï, MD; Didier Rougemont, MD; Marie-Germaine Bousser, MD; Department of CardiologyAriel Cohen, MD, PhD (coprincipal investigator); Christophe Chauvel, MD; Bouziane Benhalima, MD; Catherine Albo, MD; Éric Abergel, MD
Grenoble, Centre Hospitalier et Universitaire de Grenoble: Stroke UnitMarc Hommel, MD (local principal investigator); Gérard Besson, MD; L. Vercueil; Department of CardiologyBernard Bertrand, MD (local coprincipal investigator)
Besançon, Centre Hospitalier et Universitaire de Besançon: Department of Neurology, Jean Minjoz HospitalThierry Moulin, MD (local principal investigator); Didier Chavot, MD; Laurent Tatu, MD; Department of Cardiology, Saint-Jacques Hospital: Yvette Bernard, MD (local coprincipal investigator)
Lille, Centre Hospitalier et Universitaire de Lille: Department of Neurology, Roger Salengro HospitalDidier Leys, MD (local principal investigator); Philippe Rondepierre, MD; Christian Lucas, MD; Department of Cardiology, Cardiology HospitalLuc Goulard, MD (local coprincipal investigator); Ghislaine Deklunder, MD; Elie Chamas, MD
Dijon, Centre Hospitalier et Universitaire de Dijon: Department of Cardiology, Bocage's HospitalSylvie Falcon, MD (local principal investigator); J.-E. Wolf, MD; Department of Neurology, General HospitalMaurice Giroud, MD
Committees
The following served as committee members of the FAPS study:
EchocardiographyAriel Cohen, MD, PhD (echocardiography study design and reviewer of all echocardiography examinations); Bernard Bertrand, MD; Christophe Chauvel, MD; Yvette Bernard, MD
Data Monitoring and Coordinating CenterPierre Amarenco, MD
Data AnalysisChristophe Tzourio, MD, PhD, Unité 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Institut National de la Santé et de la Recherche Médicale, Paris
Received April 10, 1997; revision received May 28, 1997; accepted May 28, 1997.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Nakahira, T. Sawai, T. Katsumata, H. Imanaka, and T. Minami Lambl's Excrescence on Aortic Valve Detected by Transesophageal Echocardiography Anesth. Analg., June 1, 2008; 106(6): 1639 - 1640. [Full Text] [PDF] |
||||
![]() |
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Doufekias, A. Z. Segal, and J. R. Kizer Cardiogenic and aortogenic brain embolism. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1049 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Raz, U. Lindenberger, P. Ghisletta, K. M. Rodrigue, K. M. Kennedy, and J. D. Acker Neuroanatomical Correlates of Fluid Intelligence in Healthy Adults and Persons with Vascular Risk Factors Cereb Cortex, March 1, 2008; 18(3): 718 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 483S - 512S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Homma, M. R. Di Tullio, R. R. Sciacca, R. L. Sacco, J.P. Mohr, and for the PICSS Investigators Effect of Aspirin and Warfarin Therapy in Stroke Patients With Valvular Strands Stroke, June 1, 2004; 35(6): 1436 - 1442. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Chest, January 1, 2001; 119(1_suppl): 300S - 320S. [Full Text] [PDF] |
||||
![]() |
B. Censori, F. Colombo, M. G. Valsecchi, L. Clivati, A. Zonca, M. Camerlingo, L. Casto, M. S. De Tommasi, and A. Mamoli Early transoesophageal echocardiography in cryptogenic and lacunar stroke and transient ischaemic attack J. Neurol. Neurosurg. Psychiatry, May 1, 1998; 64(5): 624 - 627. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |